Key result
Inflammatory biomarkers and plaque imaging best stratify risk in polyvascular disease.
Why the study?
Atherosclerosis is the leading cause of morbidity and mortality worldwide, and management of polyvascular disease is complicated by a lack of standardized diagnostic criteria, early detection methods, and discrepancies between Russian and international clinical guidelines.
This review highlights that integrating inflammatory biomarkers (hs-CRP, IL-6, ICAM-1) and advanced plaque imaging (CCTA, PET/MRI) within a multidisciplinary approach is key to risk stratification and improving long-term outcomes in polyvascular disease.
Answers are grounded in this paper and cite their sources.
May support polyvascular risk stratification with hs-CRP/IL-6/ICAM-1 and CCTA/PET-MRI; leaves open prospective validation before adoption.
Being the leading morbidity and mortality cause worldwide, atherosclerosis represents a relevant topic in medicine. This review comprehensively analyzes the clinical course, diagnostics, and outcomes peculiar to polyvascular disease (multifocal atherosclerosis). The paper describes the disease’s systemic nature and its prevailing association with chronic inflammation and endothelial dysfunction. The most informative for risk stratification are inflammatory biomarkers, i.e. High-Sensitivity C-Reactive Protein (hs-CRP), Interleukin‑6 (IL-6), Inter-Cellular Adhesion Molecule 1 (ICAM‑1); and modern methods for imaging vulnerable atherosclerotic plaques, such as coronary computed tomography angiography (CCTA), and positron emission tomography (PET) combined with magnetic resonance imaging (MRI). It is highlighted that the application of clinical guidelines for aneurysm treatment ensures timely identification of high vascular risk in patients. In addition, the authors consider the prospects of using multibiomarker panels, molecular diagnostics, and artificial intelligence technologies for risk stratification and personalization of disorder prevention and therapy. The work also outlines outstanding related issues: the lack of standardized diagnostic criteria and early detection methods, as well as discrepancies between the Russian and international clinical guidelines. The conclusion emphasizes the need for a comprehensive, multidisciplinary approach to managing polyvascular disease, which is aimed at reducing the incidence of acute vascular events and improving long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Dushulova et al. (2026) conducted a review in Polyvascular disease (multifocal atherosclerosis). Inflammatory biomarkers (hs-CRP, IL-6, ICAM-1) and advanced imaging (CCTA, PET/MRI) was evaluated on Risk stratification, incidence of acute vascular events, and long-term outcomes. Inflammatory biomarkers (hs-CRP, IL-6, ICAM-1) and modern plaque imaging (CCTA, PET/MRI) are most informative for risk stratification in polyvascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: